Oricell Therapeutics Closes First Tranche of $70M Series C to Accelerate Global Development of Solid Tumor CAR-T Therapies
A global leader in innovative tumor immunotherapy
@author-1788515151757110
A global leader in innovative tumor immunotherapy
late-stage clinical biotech company
Qiming Venture Partners co-led Zhipu AI's Series B1 round in early 2022 — nearly a year before ChatGPT's release ignited the global large language model wave. It was this funding that enabled Zhipu AI to push through the R&D of its first 100-billion-parameter model, GLM. Qiming Venture Partners continued to back the company in its Series B2 and B4 rounds.
Over the next 5–10 years, more highly original R&D breakthroughs are expected to emerge from Chinese labs and contribute to global pharmaceutical innovation.
A bellwether for China's equity investment industry and a key reference for major institutional LPs when making allocation decisions.
We hope to highlight investment firms that were bolder in their early-stage bets and backed projects that exerted greater influence on their industries and the market at large.
Qiming Venture Partners was one of Biren Technology's earliest and most steadfast supporters. When Biren Technology was founded in 2019, Qiming Venture Partners came in as a founding investor, leading the company's first funding round, and has continued to back the company's growth ever since.
"We won't invest too early before the wave arrives, nor will we follow the crowd once the wave has fully formed. We aim to seize the moment — that 'half-step' just before the big wave hits — to find and back the most promising teams."
The year draws to a close; a new cycle begins.
Celebrating milestone moments with Qiming Venture Partners' portfolio companies